

**PROVIDER NOTIFICATION OF RETAIL DRUG
POLICY CRITERIA CHANGE**

Drug Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Prolio and Biosimilars	1) Added treatment to inhibit progression of bone erosion in Rheumatoid arthritis. 2) Added documentation required for previous therapies tried, if applicable. 3) For postmenopausal osteoporosis (OP), OP for men, glucocorticoid-induced OP (GIOP) - removed 1 year trial of bisphosphonates (BP) or clinical reason to avoid BP and updated to "has had an inadequate response or intolerance to previous BP therapy." 4) For postmenopausal OP initial criteria, updated "failed prior treatments to previous injectable OP therapy" to "had an inadequate response or intolerance to". 5) For OP for men initial criteria, updated to allow high fracture risk OR inadequate response to BP therapy, OR history of osteoporotic vertebral/hip fracture. 6) For GIOP initial criteria, updated to allow either high/very high fracture risk OR inadequate response/intolerance to previous BP therapy. 7) The program was updated to include the new biosimilar Osvyrti (denosumab-desu) and Boncresa (denosumab-mobz).	5/10/2026	Standard, Metallic, and Essential
Cosentyx	Expanded the FDA-approved indication for hidradenitis suppurativa (HS) to include pediatric patients 12 years of age and older (previously approved in adults only).	05/10/2026	Standard, Metallic, and Essential
Sotyktu	Added newly FDA-approved indication for the treatment of active psoriatic arthritis in adults.	05/10/2026	Standard and Essential